43 results on '"Caye-Eude, Aurélie"'
Search Results
2. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study
3. Partitioning for Easy Multiplexing: A Versatile Droplet PCR Application for Clone Monitoring in Tumors
4. Success of donor‐derived CAR‐T cells after failure of autologous CD19 CAR‐T cells (tisagenlecleucel) in B‐cell acute lymphoblastic leukaemia
5. The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia
6. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
7. A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
8. A PAX5 P80R pediatric B acute lymphoblastic leukemia with monocytic lineage switch at diagnosis: Deciphering classification ambiguity
9. Mise au point sur les leucémies aiguës de lignée ambiguë en 2023 – Recommandations du comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE)
10. P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL
11. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions
12. The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome
13. The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial
14. 3109 – IDENTIFICATION OF B LINEAGE COMMITMENT MARKERS FOR GENE EXPRESSION-BASED RISK STRATIFICATION OF INFANT KMT2A::AFF1 ACUTE LYMPHOBLASTIC LEUKEMIA
15. The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial.
16. Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
17. Two Distinct Fetal-Type Signatures Caracterise Juvenile Myelomonocytic Leukemia
18. Impaired OTUD7A-dependent Ankyrin regulation mediates neuronal dysfunction in mouse and human models of the 15q13.3 microdeletion syndrome
19. KMT2A-CBLrearrangements in acute leukemias: clinical characteristics and genetic breakpoints
20. Targeted Next Generation Sequencing Reveals a Third Breakpoint Cluster Region and New Partner Genes in the KMT2A Recombinome
21. Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia
22. Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia
23. Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
24. Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
25. JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators
26. B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL
27. Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience
28. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions
29. Large deletions of the 5′ region of IKZF 1 lead to haploinsufficiency in B‐cell precursor acute lymphoblastic leukaemia
30. MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis
31. KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
32. Large deletions of the 5′ region of IKZF1 lead to haploinsufficiency in B‐cell precursor acute lymphoblastic leukaemia.
33. Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy
34. Human MLL/KMT2Agene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions
35. B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL
36. Immunophenotypic Profiling of Childhood B-Cell Precursor Acute Lymphoblastic Helps Identifying Genetic Subtypes, Including Recently Identified Ones
37. Outcomes of infants with very late relapse of acute lymphoblastic leukaemia initially treated in Interfant‐06.
38. B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/ IL3-IGHRearrangement and Eosinophilia: A Peculiar IGHBCP-ALL
39. KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
40. CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
41. Differential activation of basal and IL-7-induced PI3K/Akt/ mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia.
42. Germline bi-allelic SH2B3/LNK alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder.
43. The prognostic value of IKZF1 plus in B-cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.